Pharvaris, N.V (PHVS)

NASDAQ: PHVS · IEX Real-Time Price · USD
19.44
+0.44 (2.32%)
At close: Aug 18, 2022 4:00 PM
18.42
-1.02 (-5.25%)
After-hours: Aug 19, 2022 4:00 PM EDT
2.32%
Market Cap 644.48M
Revenue (ttm) n/a
Net Income (ttm) -57.93M
Shares Out 33.15M
EPS (ttm) -1.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,092
Open 18.75
Previous Close 19.00
Day's Range 18.31 - 19.44
52-Week Range 13.14 - 27.50
Beta n/a
Analysts Buy
Price Target 40.46 (+108.1%)
Earnings Date Aug 19, 2022

About PHVS

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 cli... [Read more...]

Industry Biotechnology
IPO Date Feb 5, 2021
Employees 41
Stock Exchange NASDAQ
Ticker Symbol PHVS
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for PHVS stock is "Buy." The 12-month stock price forecast is 40.46, which is an increase of 108.13% from the latest price.

Price Target
$40.46
(108.13% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference

ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, buildin...

Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13

ZUG, Switzerland, July 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, buildin...

Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, buildin...

Pharvaris Participates in the Kinin 2022 Conference

Pharvaris' tailored drug development approach to enable treatment of people living with all types of hereditary angioedema (HAE) presented at satellite symposium Pharvaris' tailored drug development app...

Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-)

ZUG, Switzerland, May 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building...

Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer

ZUG, Switzerland, May 11, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building...

Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights

ZUG, Switzerland, May 11, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building...

Pharvaris to Participate in BofA Securities 2022 Healthcare Conference

ZUG, Switzerland, May 05, 2022 (GLOBE NEWSWIRE) --  Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, buildin...

Pharvaris to Participate in Upcoming April Investor Conferences

ZUG, Switzerland, April 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, buildi...

Pharvaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

ZUG, Switzerland, March 29, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, buildi...

Pharvaris Announces Preclinical Pharmacological Data for Small Molecule PHA121 Published in International Immunopharm...

Data demonstrate PHA121 to be a potent human bradykinin B2 receptor antagonist Data demonstrate PHA121 to be a potent human bradykinin B2 receptor antagonist

Pharvaris to Participate in 11th Annual SVB Leerink Global Healthcare Conference

ZUG, Switzerland, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...

Pharvaris Announces Changes to its Board of Directors

ZUG, Switzerland, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...

Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights

ZUG, Switzerland, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...

Pharvaris to Participate in Upcoming September Investor Conferences

ZUG, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists ...

Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights

ZUG, Switzerland, July 30, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...

Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the...

Multiple doses of PHA121 were well-tolerated and showed a favorable pharmacokinetic profile for prophylactic treatment of HAE Multiple doses of PHA121 were well-tolerated and showed a favorable pharmaco...

Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021

ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...

Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of H...

ZUG, Switzerland, June 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...

Pharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights

ZUG, Switzerland, May 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists fo...

Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights

ZUG, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the ...

Pharvaris to Participate in BioCapital Europe

ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the ...

Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE

ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the t...

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI ...

Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers

Pharvaris Announces Closing of Initial Public Offering

ZUG, Switzerland, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”) (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...